Sharing Publication-Related Data and Materials Responsibilities of Authorship in the Life Sciences (2003) / Chapter Skim
Currently Skimming:
Appendix B: Workshop Agenda and Situations
Appendix B: Workshop Agenda and Situations
Pages 89-104
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 89... ...
Dr. Cech 9:35 Panelists Response: Maria Freire, CEO, Global Alliance for TB Drug Development (former director of NIH Of lice of Technology Transfer)
|
From page 90... ...
Genome Sequences of Quantitative Trait Loci Rapporteur: Robert Hazelkorn, Fanny L.. Pritzker Distinguished Service Professor, Department of Molecular Genetics and Cell Biology, University of Chicago 2c (10 min)
|
From page 91... ...
Dr. Cech 2:20 Panelists Response: Ari Patrinos, Associate Director, Office of Biological and Environmental Research Office of Science, Department of Energy James Wells, President and Chief Scientific Officer, Sunesi: Pharmaceuticals, Inc.
|
From page 93... ...
A well-known senior investigator publishes a paper with others in his lab, including two graduate students, in which knockout mice are generated and characterized, in part, with a polyclonal antibody. The mice reproduce poorly and the investigator plans on using the antibody for many further experiments and only has a limited amount of the reagent.
|
From page 94... ...
What is a reasonable time to allow someone to turn around a request for a reagent? Under what circumstances is it fair for the senior investigator to request collaboration in exchange for a published material?
|
From page 95... ...
A team funded by NIH submits a short article for publication to a leading journal Neural Hieroglyphica which comprises an analysis of functional and physical changes in the brains of schizophrenics, based on the results of several detailed fl~RI-imaging procedures.
|
From page 96... ...
facilities and without a medical school, and is in no position to acquire similar primary data. He finds that the conclusions to the short article do not fit with his anatomical studies of the brains of deceased schizophrenics, and wonders if there is an alternate interpretation of the primary data.
|
From page 97... ...
They report detailed biological studies, including field tests under conditions of abundant water, limiting water, and extreme drought that show a strong correlation of drought resistance with the presence of markers for the CUTE in different germplasm. Because they haven't pinned down a gene yet, they do not want to publish any of the sample sequencing data.
|
From page 98... ...
As written, it would be difficult, but not impossible, for others to reproduce the work; they would have to obtain the original lines (which would be in the public domain) and do several cycles of crosses to recreate germplasm from which, following the procedures in the paper, the markers could be isolated.
|
From page 99... ...
Does the investigator have a responsibility to consider the provider's interests in its materials? The Gendefox company is a small biotech company that wants to allow its investigators to publish, and is wiring to give academic investigators access to materials referred to in its investigators' publications with a material transfer agreement (MTA)
|
From page 100... ...
Lawyers in the company are against permitting company investigators to publish if it means handing over materials for academic research. They point out that publications they have reviewed prior to publication describe a plethora of discoveries surrounding the company's materials and reveal information the company does not want its competitors to have.
|
From page 101... ...
Workshop Situations How does or how should a company evaluate the pluses and minuses of publishing in academic journals? What is the reality of the "timing" of publications in the academic and for-profit sectors?
|
From page 102... ...
Does repeatability of science that involves complicated software or databases require complete access to computer source code and raw data, or only the possibility of running the code and interrogating the database?
|
From page 103... ...
In 2015, the Cardiomics company announces that its proprietary model of the human heart (Virtual Heart) is complete, including heart models reflecting various stages of cardiovascular disease, genetic disorders, and the consequences of infarction.
|
From page 104... ...
What restrictions should Cardiomics be allowed to put on any data release to protect its proprietary interests? Would this be any different for a large pharmaceutical company with less at risk than a small bioinformation company like Cardiomics or for an academic lab trying to protect itself from academic competition?
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.